Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer - Wikidata - wikimedia - TriplyDB

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

http://www.wikidata.org/entity/Q28288814

about

Challenges in the clinical utility of the serum test for HER2 ECD Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens Plasma membrane proteomics and its application in clinical cancer biomarker discovery.Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.Primary trastuzumab resistance: new tricks for an old drug.Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?Predicting brain metastases of breast cancer based on serum S100B and serum HER2.Lapatinib: new opportunities for management of breast cancer.Serum HER2 levels determined by two methods in patients with metastatic breast cancer.Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.P95 HER2 fragments and breast cancer outcome.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.Caveolin-1 is involved in radiation-induced ERBB2 nuclear transport in breast cancer cells.Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients.Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting.Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays.

P2860

Q26861754-F4B9AC1E-C7ED-4876-AF0E-0B26BC4FBD16 Q28077666-C90BBFFF-6D55-442A-8D84-4B6E0968DA57 Q33735413-415410D2-B139-4512-BFAD-AF1A7EF2B87D Q34122107-0C936262-6E8F-4488-A2C7-2365BAE5FD8D Q34315003-48BA1C01-40FB-41A9-B96E-1359B44E2F05 Q34610251-187826C7-DFEB-4EC0-935F-13D7425F09E0 Q36299086-FFBBA5BA-CCA2-49BB-BEA9-E77D4B739943 Q36591915-6185EFAB-F60B-4F78-8845-550AD9B62B07 Q36727464-9C8F1AEA-CDD0-4C23-8EAB-67AA890C6BD3 Q37218987-DAA18003-3267-4FBB-82FD-9CE2E5DEB317 Q37269532-6B1E487D-0F16-4C54-B16E-0C6B217725A4 Q37355729-BD8ED945-FA89-4606-A9C6-9F0E6A027221 Q37386272-A88B0100-6395-4D44-A020-1D1BA67E58E8 Q37676772-75F54280-587B-45DD-8AA6-7E16E139E2E0 Q37690705-1D760465-B0C7-4637-A0F6-49C93E9CE514 Q37802782-76F8BB1E-D5B9-4347-BA2E-F1610A9523CF Q38223511-146DB561-F695-4C1D-AAE7-6FF7A200A337 Q38612634-63AB33DE-3FE7-405A-89EA-5A969B286773 Q38859024-517172FB-8CDA-42D3-9D56-55B54AA28333 Q38875316-8A416912-150C-42F1-AC64-7B0DD9157DC0 Q39220082-2DC7521C-A524-48F2-AFD9-6EB1398DB988 Q44056799-D780ECD7-3F04-4A0A-A112-EA4D6FD70EC8 Q48173008-DDA00C3D-2915-454B-976F-E8F7401026BF Q53223448-EE7C521F-EE02-4914-8749-C1E57422A7ED Q54599560-AF746A3F-7B7D-43E6-A2A5-F927D22ACBA8 Q54722626-81EF6CE4-4C60-4409-9794-E4D967806694 Q55715013-0F447147-1AE0-4A2B-9EE3-DA1DE38AD144

P2860

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

http://www.wikidata.org/entity/Q28288814

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@ast

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@en

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@nl

type

label

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@ast

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@en

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@nl

prefLabel

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@ast

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@en

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@nl

P1433

Q28288814-F0A06D8F-149C-4346-BFD8-CDC092178B16

P1476

Q28288814-06E7276E-0BE7-4590-B53E-013B3EB35C6E

P2093

Q28288814-0CFE7B00-61A9-48BB-945B-6DE208AD6912

Q28288814-33B54D6E-7498-4AFB-BDCE-606AA70D8651

Q28288814-48518EE6-5F82-4F5F-9736-97081F91DBE3

Q28288814-8AAC2826-E8CB-4BB1-8CFA-11DB755BEC83

Q28288814-92584EA4-E5ED-4D23-A85C-58B31F13EBFD

Q28288814-B6B3DC4D-DF94-45E8-B5DA-8F635F4FFAAD

Q28288814-D62CBFE4-5654-4A02-B19B-25F7DBB86E2B

Q28288814-E39D2956-1089-4332-BD0D-EE7C74D8A71F

Q28288814-E5662574-E8B6-46FD-AE28-6CBB7D2D5C3F

Q28288814-F6AB6BA9-85F3-4441-B293-42279D8D10DA

P304

Q28288814-FABE583A-CABA-4609-991A-AAA9FB1A6977

P31

Q28288814-1E07B820-6A88-41CB-9049-65F6F5FDAC41

P356

Q28288814-F16183E5-D59F-4E7B-BB4F-1F5751752931

P407

Q28288814-59C0E81F-74BF-4FEB-A588-A72A0C908037

P433

Q28288814-A33ADFBD-60D3-43B4-9359-7AD568D03D60

P478

Q28288814-05218482-F699-4461-832D-9FA34307AD6B

P50

Q28288814-93145C7D-1EBE-47E9-AB98-636B7ACF0802

P577

Q28288814-2B2BE9AB-E3BF-4B33-B79A-939F66C147B1

P5875

Q28288814-EC76CA2D-BD9D-47A0-BF3B-607B6CA6A9B0

P698

Q28288814-8BC9FCF3-C3A6-46D9-BA8E-DA487169FCC2

P356

P1433

P1476

Serum HER-2/neu and relative r ...... with metastatic breast cancer

@en

P2093

Allan Lipton

http://www.w3.org/2001/XMLSchema#string

Diana Luftner

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Lotz

http://www.w3.org/2001/XMLSchema#string

Lyndsay Harris

http://www.w3.org/2001/XMLSchema#string

Marie-France Pichon

http://www.w3.org/2001/XMLSchema#string

Monica Fornier

http://www.w3.org/2001/XMLSchema#string

Serum HER-2/neu Study Group

http://www.w3.org/2001/XMLSchema#string

Suhail M Ali

http://www.w3.org/2001/XMLSchema#string

Walter P Carney

http://www.w3.org/2001/XMLSchema#string

Wolfgang J Köstler

http://www.w3.org/2001/XMLSchema#string

P304

1294-1301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.23689

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Francisco J Esteva

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51432341

http://www.w3.org/2001/XMLSchema#string

P698

18661530

http://www.w3.org/2001/XMLSchema#string